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Feature ReviewGrowth hormone deficiency (GHD) of the adult is char-
acterized by reduced quality of life (QoL) and physical
fitness, skeletal fragility, and increased weight and car-
diovascular risk. Hypopituitarism may develop in
patients after definitive treatment of acromegaly, but
an exact prevalence of GHD in this population is still
uncertain owing to limited awareness and the scarce and
conflicting data available on this topic. Because acro-
megaly and GHD may yield adverse consequences on
similar target systems, the final outcomes of some com-
plications of acromegaly may be further affected by the
occurrence of GHD. However, it is still largely unknown
whether patients with post-acromegaly GHD may bene-
fit from GH replacement. We review the diagnostic,
clinical, and therapeutic aspects of GHD in adult patients
treated for acromegaly.
Introduction
Acromegaly is a chronic disease characterized by excess
secretion of growth hormone (GH), generally caused by a
pituitary macroadenoma (70% of cases), which results in
the elevation of circulating levels of GH and insulin-like
growth factor (IGF)-I [1]. The estimated prevalence of
acromegaly is approximately 40–70 patients per million,
with an incidence of 3–4 new cases per million every year
[2,3]. Although a relatively rare disease, acromegaly is
associated with reduced life expectancy in strict relation-
ship with GH hypersecretion and comorbidities such as
cardiovascular, respiratory, metabolic, and neoplastic com-
plications [4,5].
Therapies and treatment modalities for acromegaly
aim to reduce or control tumor growth, inhibit GH hyper-
secretion, and normalize IGF-I values to improve quality
of life (QoL) and reduce morbidity and mortality associat-
ed with GH and IGF-I excess [6]. As a matter of fact, the
therapy should ideally be directed to the restoration of
physiological GH secretion, which is achieved when the
tumor is removed, such that the response of GH to dynamic
stimuli and its integrated daily secretion are normalized.1043-2760/
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radiotherapy; mortality.However, several acromegaly patients receiving treat-
ment do not achieve complete normalization of GH secre-
tion [7]. Some patients maintain high serum GH and IGF-I
values, whereas others may develop GHD as a result of
overtreatment of acromegaly.
GHD of the adult is now recognized as a well-defined
clinical condition, characterized by reduced QoL and phys-
ical fitness, skeletal fragility, adiposity, and increased
cardiovascular risk [8]. All these complications of GHD
may be clinically relevant in patients with a history of
acromegaly who have already developed cardiovascular,
metabolic, and skeletal complications [9]. Although GHD
has been extensively characterized in relation to its pri-
mary causes, the exact prevalence of this clinical condition
in patients treated for acromegaly is still uncertain be-
cause of low awareness and scarce and conflicting data in
the literature on this topic [10–20]. Moreover, it is largely
unknown whether patients with post-acromegaly GHD
may benefit from replacement with GH [21–24].
This review deals with the emerging clinical challenge
of GHD in adult patients undergoing treatment for acro-
megaly, focusing on diagnostic, clinical, and therapeutic
aspects of this condition.
Current management options in acromegaly
Multimodal treatment is often necessary to control acro-
megaly by suppressing GH hypersecretion, reducing IGF-I
levels, and controlling tumor growth, leading to symptom
control and minimizing the associated clinical signs and
comorbidities [6]. The three approaches to therapy are
surgery, medical management, and radiotherapy. Each
treatment modality has specific advantages and disadvan-
tages, but the optimal use of these treatments should theo-
retically result in reducing mortality in the acromegaly
patient population to that of the general population [4,5].
Transsphenoidal surgery is the treatment of choice for
intrasellar microadenomas, noninvasive macroadenomas
(i.e., those without cavernous sinus or bone invasion), and
when the tumor is causing compression symptoms
[6,25,26]. In patients with intrasellar microadenomas, sur-
gical removal provides biochemical control with normali-
zation of IGF-I in 75–95% of patients, whereas control
rates are much lower in patients with macroadenomas
[6]. Options for such latter tumors include primary medical
therapy or primary surgical debulking followed by medicalTrends in Endocrinology and Metabolism, January 2015, Vol. 26, No. 1 11
Feature Review Trends in Endocrinology and Metabolism January 2015, Vol. 26, No. 1therapy for hormonal control and/or radiation therapy for
treatment of residual tumor [6].
Three forms of medical therapy have been used in the
treatment of acromegaly [27]. Long-acting formulations of
somatostatin analogs currently approved for clinical use, in
other words octreotide long-acting release and lanreotide
autogel, are the primary medical treatment option if surgery
is not appropriate and are the primary first-line therapy
after surgery [27,28]. These drugs signal via somatostatin
receptor subtype 2, and to a lesser extent by targeting
receptor subtype 5, leading to a decrease in GH secretion
and to tumor shrinkage [29,30]. About 50% of patients
treated with these drugs achieve full biochemical control
of acromegaly, although this percentage was shown to de-
cline when data from registries of unselected patients were
considered [7,31]. The dopamine agonist cabergoline, which
targets type 2 dopamine receptors on pituitary adenomas,
may retain some advantage in treating acromegalic patients
with biochemically mild disease [32,33]. Patients unrespon-
sive to somatostatin analog therapy are switched to pegvi-
somant, a drug capable of blocking GH receptor and
reducing liver IGF-I production [34,35]. In initial multicen-
ter trials, serum IGF-1 levels were normalized in more than
90% of patients treated with pegvisomant, while drug effec-
tiveness was somewhat lower in open-label or postmarket-
ing studies performed in clinical settings or based on
retrospective analysis of disease-specific databases
[34]. In some patients, who do not respond to medical
monotherapy and/or require tumor mass control, combina-
tion therapies with somatostatin analogs plus cabergoline,
somatostatin analogs plus pegvisomant, or pegvisomant
plus cabergoline have been proposed [27,34,35].
Radiation therapy should generally be scheduled as
third-line treatment, occasionally as second-line treat-
ment, but rarely as first-line treatment [6]. Patients who
do not have tumor growth control or normalization of
hormone levels with surgery and/or medical therapy are
possible candidates for radiation therapy. Conventional
radiotherapy can lower GH levels and normalize IGF-I
in over 60% of patients, but maximal response is achieved
10–15 years after radiotherapy is administered [6]. Before
the generation of modern medical therapies, conventional
radiotherapy was used as a second-line option when sur-
gery failed to control GH/IGF-I hypersecretion, but this
approach was burdened by variable efficacy, long time to
reach complete effectiveness, high prevalence of hypopitu-
itarism, increased cerebrovascular mortality, and in-
creased risk of secondary brain tumors in recipient
patients [6]. More recently, stereotactic radiosurgery tech-
niques, such as gKnife, have been used in patients with
acromegaly with the aim of avoiding irradiation of normal
brain and minimizing the long-term consequences of ra-
diotherapy while improving its effectiveness [6,13,16,19],
but very long-term data on safety and efficacy of these
newer approaches are still lacking. Moreover, stereotactic
neurosurgery may cause optic neuropathy more often than
conventional radiotherapy in patients with tumor remnant
too close to the optic pathways [6]. In fact, choice of the
technique is dependent upon the tumor characteristics:
conventional radiotherapy is preferred for large tumor
remnants or tumors that are too close to optic pathways,12whereas gKnife is preferred when there is a smaller tumor
size or when improved patient convenience is desired [6].
Criteria for cure of acromegaly
Before 2000 there was a wide variability in the criteria
arbitrarily used for defining biochemical control of acro-
megaly in different settings. The first historical step to
define the biochemical control of acromegaly was the Cor-
tina Consensus Conference which, for the first time, estab-
lished general criteria for universal use based on the
concept that both GH and IGF-I should be ‘normalized’
for a complete control of disease [36]. Thereafter, several
subsequent studies and reappraisals did challenge the
validity of the consensus criteria and called for their revi-
sion [37]. Optimal disease control (i.e., post-treatment
remission of acromegaly) is now defined as IGF-I level
(determined by a reliable standardized assay) in the
age-adjusted normal range and a GH level less than
1.0 mg/L from a random GH measurement (using an ultra-
sensitive assay) [37]. In patients with acromegaly under-
going surgical management of GH-secreting tumors, oral
glucose-tolerance test can be used to assess the outcome
and a nadir GH levels less than 0.4 mg/L (with ultrasensi-
tive assays) may define control in these circumstances
[37,38]. Normalization of IGF-I is the only reliable marker
of disease control under pegvisomant [34,37].
Risk of GHD in acromegaly with different treatments
In an effort to achieve biochemical remission in patients
with acromegaly, it is predictable that a proportion of
patients may be rendered GHD when subjected to proer-
adicative treatments. In fact, as the cure criteria for acro-
megaly have become stricter, the space between definitive
cure on one side and subnormal GH secretion on the other
has become narrower. GHD is not expected to occur in
acromegaly patients undergoing medical therapies be-
cause dosing can be finely adjusted on the basis of serum
GH and/or IGF-I values [27,34,39]. However, it is concep-
tually possible that a state of functional GHD may occur in
some medically treated patients, mainly when pegviso-
mant is used. Nevertheless, the risk of drug-induced func-
tional GHD in acromegaly is still unknown, whereas there
has been convincing evidence that radiotherapy and to a
lesser extent neurosurgery may cause GHD in this clinical
context, as has been demonstrated for other pituitary
diseases [8]. Overtreated acromegaly may be considered
a distinct category of disease outcome, and attention
should be paid to prevent it when possible and particularly
during pharmacological treatment.
GHD post-neurosurgery
Hypopituitarism may be present at diagnosis of acromeg-
aly owing to the effects of compression of a macroadenoma
on the portal vessels in the pituitary stalk and/or the
surrounding pituitary gland [1]. Successful surgery is
expected to resolve GH hypersecretion and at the same
time to immediately restore normal pituitary function
[40]. However, experience from patients with other histo-
types of pituitary adenomas suggests that GH is less likely
to recover compared to gonadotropins, corticotropin, and
thyrotropin once the tumor bulk is removed [41]. In some
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with potential consequences on the QoL and survival of
the patient [8,42]. In published surgical series, the inci-
dence of hypopituitarism after removal of GH-secreting
tumor was variable, but only few studies investigated the
GH reserve in acromegaly patients undergoing neurosur-
gery (Table 1). In some studies the prevalence of post-
surgical GHD was less than 10% [17,20], whereas others
reported greater frequencies of GHD exceeding 50% of
acromegaly patients who were defined as cured from the
disease after neurosurgery [15]. Differences in the reported
rates of severe GHD may be attributable to differences in
selection criteria for dynamic testing, tumor size, methods
used to evaluate GH secretory function, interval after
surgical procedure, metabolic background, and manipula-
tion of the pituitary gland during surgery. It was argued
that the incidence of severe GHD in surgically cured
acromegalics was lower than that observed in patients
with nonfunctioning pituitary adenomas, likely in relation-
ship to the growth direction of somatotropinomas that
often grow inferiorly, without dislocation or compression
of the pituitary gland. In fact, when the tumor was shown
to involve bilaterally the pituitary gland, the risk of GHD
tended to be significantly higher [20]. The risk of GHD was
also shown to correlate with the dimension of the somato-
tropinoma and serum GH levels before and soon after
neurosurgery [15,20].
The introduction of the endoscope to transsphenoidal
pituitary surgery could offer the surgeon better visualiza-
tion as well as an improved range of motion compared to
the operating microscope, although it is still unclear
whether the incidence of post-surgical hypopituitarism
may be reduced by using this new procedure [25,43].
GHD post-irradiation
Hypopituitarism is a well-recognized sequela of radiother-
apy for pituitary tumors, and GH is usually the first
hormone affected [44]. It was shown that 30–69% of acro-
megaly patients developed GHD after conventional frac-
tioned radiotherapy [10,15]. GH status evolves with time
after cranial radiotherapy and depends on dose, and theTable 1. Results of studies investigating the risk of growth hormo
surgery and/or radiotherapy (RT) and/or radiosurgery (RS)a
Ref. Median/mean
follow-up
(months)
Patients
(n)
Sex
(M/F)
Median/mean
age (years)
Tre
[11] 131 90 44/46 61 Sur
[15] 60 56 23/33 54 Sur
[17] 186 81/105 NS Sur
[18] NS 72 25/47 51 Sur
[20] 49 123 60/63 44 Sur
[10] 180 36 23/13 44 Sur
[12] 108 33 11/22 49 Sur
[13] 66 61 32/29 47 RS 
[14] 167 57 38/19 38 Sug
[16] 114 35 17/18 45 Sur
[19] 61 136 62/74 44 Sur
aAbbreviations: F, female; GHRH, growth hormone releasing hormone; GHRP-2, grow
insulin-tolerance test; M, male; n: number; NS, not specified; SDS, standard deviationlikelihood of GHD is greater than 50% if the biological
effective dose is greater than 40 Gy [45]. The younger the
patient, the longer the interval after radiotherapy, and the
higher the dose, the greater is the chance of developing
GHD after irradiation. The risk of hypopituitarism was
shown to be lower in patients treated by stereotactic
radiosurgery compared to conventional fractioned radio-
therapy [13,46], although in some cases the incidence of
hypopituitarism induced by stereotactic radiosurgery was
not low, and appeared to be in close relationship with the
radiation dose to the tumor margin and the way hormonal
deficiencies were ascertained [16,19].
Diagnosis of GHD in (over)treated acromegaly
(acroGHD)
Assuming that no clinical feature can be relied on as a
guide, as for auxological criteria in children, the approach
to diagnosing GHD in adults must include a high index of
suspicion. The diagnosis is often not easy, especially in
clinical conditions, such as acromegaly, in which there are
persistent qualitative abnormalities in GH secretion espe-
cially following irradiation [47,48] (Table 1).
As in the general hypopituitary population, having
normal age-adjusted levels of IGF-I does not exclude a
diagnosis of GHD also in patients with treated acromegaly
[39,49]. However, a low IGF-I level, in the absence of
catabolic conditions such as poorly controlled diabetes,
liver disease, and oral estrogen therapy, is good evidence
for significant GHD, and may be useful in identifying
patients who may benefit from treatment and therefore
require GH stimulation testing [39]. When expressed as
standard deviation score, serum IGF-I levels less than two
standard deviations below the age-matched mean are
highly suggestive of GHD [50]. Analysis of the Pfizer
International Metabolic Database (KIMS) suggests that,
in the clinical practice, serum IGF-I values have been often
used by clinicians to guide the selection of acromegaly
patients to be investigated for GHD [24]. In fact, low
IGF-I values were found to be more frequent in patients
with post-acromegaly GHD compared to those with a
history of non-functioning adenoma [24]. Mean IGF-Ine deficiency (GHD) in patients with acromegaly undergoing
atments Stimulating
tests for diagnosis
of GHD
Frequency
of severe
GHD
Median/mean
serum IGF-I in
GHD
gery GH day profile 22%
gery/RT GHRH+arginine 61% 1.1 SDS
gery GHRP-2/Arginine 9.1% 1.180 SDS
gery ITT 12.5% 0.38 SDS
gery ITT 9.8% 176 ng/ml
gery+RT ITT 36% NS
gery+RT/RS Ghrelin 27.3% 146.2 ng/ml
ITT 5.7% NS
ery+RT NS 5.8% NS
gery+RS GHRH+arginine 13% NS
gery+RS ITT NS NS
th hormone releasing peptide 2; IGF-I, insulin like growth-factor-1; ITT,
 score.
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are also significantly decreased compared to those mea-
sured in cured patients with GH sufficiency [17,42]. Also
relevant is the finding of a longer duration of GHD in some
patients with previous history of acromegaly, which likely
reflects low clinician awareness of the risk of GHD in
patients in remission [21,24]. By contrast, some authors
based their diagnostic assumption of GHD exclusively on
IGF-I levels when three or more pituitary hormone defi-
ciencies were present [50–53].
In other cases, stimulation testing is mandatory for
diagnosis of GHD in acromegaly patients, as well as in
those with other pituitary diseases. GH production is
largely under hypothalamic control including GH releasing
hormone (GHRH) and somatostatin, which stimulate and
inhibit secretion, respectively [47]. In the early 1980s a
class of synthetic peptidyl compounds, collectively termed
GH secretagogs, were shown to stimulate GH release both
in vivo and in vitro [54]. Ghrelin, which is the natural
ligand of GH secretagog receptor, mediates the release of
GH by increasing GHRH and decreasing somatostatin
neuronal activity within the hypothalamus [54]. It also
directly stimulates GH release from pituitary somato-
tropes. In addition to classic and ‘non-classic’ hypothalamic
peptides, many other neuropeptides (galanin), neurotrans-
mitters (acetylcholine), metabolic signals (fasting, hypo-
glycemia, aminoacids) and peripheral hormones (thyroid
and sex hormones) are involved in the modulation of GH
secretion [47,55–60].
The insulin-tolerance test (ITT) is the gold standard in
establishing the diagnosis of GHD in adults and the GHRH
in conjunction with arginine (GHRH+arginine) test was
shown to give comparable results [52,53,61,62]. Notwith-
standing possible variability related to individual factors
(age, body composition, etc.) and different GH assays, 3 mg/
L is traditionally considered the cut-off for diagnosis of
severe GHD in adults as assessed by ITT [52,53], whereas
different cut-offs have been proposed for the GHRH+argi-
nine test in relationship to body mass index (BMI). Corneli
et al. [63] showed that the appropriate GH cut-off points for
diagnosing GHD were 11.5 mg/L for patients with a BMI
less than 25 kg/m2, 8.0 mg/L for a BMI within 25–30 kg/m2,
and 4.2 mg/L for those with a BMI greater than 30 kg/
m2. Both ITT and GHRH+arginine tests have been used
to investigate GH secretion in patients with treated acro-
megaly, with positive correlation between the peak GH
responses to the two tests [64]. As an alternative to ITT and
GHRH+arginine, some authors proposed to use GHRH
alone or ghrelin-mimetic GH secretagogs to stimulate
GH secretion in patients with acromegaly [12,65]. These
tests were shown to be reliable in patients previously
treated by surgery, whereas the results could be mislead-
ing in patients treated with conventional radiotherapy who
could show abnormal response to ITT and arginine, but can
retain a normal or low-normal response to GHRH and
ghrelin-mimetic GH secretagogs [65]. In fact, the response
to ITT and arginine requires an intact somatostatin axis,
which indeed is more vulnerable to radiation-induced
damage than the GHRH axis and pituitary parenchyma
[66]. As a matter of fact, GHRH+arginine test was shown to
be unreliable for diagnosis of GHD when performed in the14first 5 years after conventional radiotherapy [67], whereas
data in patients treated with gKnife are still lacking.
Evolution of spontaneous GH secretion may be of help in
patients with equivocal GH response to stimulating tests
[68,69]. In fact, patients developing GHD after acromegaly
show abnormalities of spontaneous GH secretion, with
specific attenuation of the size of GH bursts and a highly
irregular pattern, but with retained circadian properties
[70], which are comparable to those occurring in patients
developing GHD after radiotherapy for other pituitary
adenomas [64]. By contrast, some cranially irradiated
adult patients with isolated abnormal response to stimu-
lating tests may transiently show near-normal spontane-
ous GH secretion likely reflecting an initial compensatory
increase in hypothalamic stimulatory input within a par-
tially damaged hypothalamic–pituitary axis [71].
Clinical features of GHD in (over)treated acromegaly
(acroGHD)
The clinical significance of GHD in overtreated acromegal-
ic patients is explained by the pleiotropic effects of GH and
IGF-I on lipolysis, gluconeogenesis, bone formation, mus-
cle anabolism, and psychological well-being. Patients with
acromegaly have a considerable burden of complications
and coexisting illnesses, such as cardiomyopathy, hyper-
tension, diabetes mellitus, sleep apnea, osteoarthropathy,
and fragility vertebral fractures, which lead to different
extents to an impairment of QoL and shortened life expec-
tancy [9,72–74]. On the other side, adult GHD is associated
with high cardiometabolic risk due alterations in body
composition, lipoprotein profile, fibrinolytic activity, and
endothelial function [75–77]. Moreover, GHD is associated
with feelings of social isolation, fatigue, and poorer QoL
[78], and high risk of fragility fractures [79]. If GHD is left
untreated, mortality rates double compared to the refer-
ence population [80]. Nonetheless, controversial opinions
exist on beneficial effects of long-term GH therapy on
mortality rates in GHD [81].
GHD in patients treated for acromegaly (acroGHD):
pathophysiological aspects
GH excess and defects share some clinical features
(Figure 1). Thus, it is conceivable that the transition from
active acromegaly to GHD may have severe impact on
several targets, such as the cardiovascular system and
the skeleton, with consequent progression of some clinical
complications already caused by GH excess.
Hypertension and insulin resistance may be persistent
in several patients with acromegaly even after adequate
biochemical control of GH hypersecretion [82,83]. In this
specific clinical context, it is expected that the occurrence of
GHD, with consequent negative effects on body composi-
tion and endothelial function, may favor hypertension and
insulin resistance, with further increase of cardiovascular
risk and mortality. It is worth mentioning that GHD also
favors accelerated atherosclerosis and coronary artery
disease [75].
GH exerts direct effects on myocardial growth [84], and
the occurrence of GHD is expected to decrease ventricular
mass in patients with persistent acromegalic cardiomio-
pathy. Although GH may also exert positive effects on
rhGH
treatment
Untreated
GHD
Acromegaly
Quality of life
Fracture risk
Cardiovascular risk
Mortality
Diabetes
Hypertension
Neoplasc risk
Cerebrovascular risk
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Figure 1. Clinical domains shared by acromegaly, untreated, and replaced growth
hormone deficiency (GHD). Untreated GHD and acromegaly share impaired quality
of life and high fracture, cardiovascular, and mortality risk. The replacement of
GHD by human recombinant growth hormone (rhGH) may cause complications
(i.e., hypertension, diabetes, high neoplastic, and cardiovascular risk) which are
similar to those occurring in acromegaly.
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theoretically lead to heart failure in predisposed patients
with pre-existing cardiac abnormalities [69,86], such as
those with acromegalic cardiomyopathy [87].
GH excess and deficiency have opposite effects on bone
turnover, but both lead to skeletal fragility and high risk of
vertebral fractures [88]. Interestingly, although appropriate
and effective treatment of acromegaly improves skeletal
health [89–91], the risk of vertebral fractures may persist
high in some patients with well-controlled or cured acro-
megaly, in close relationship with pre-existing vertebral
fractures and untreated hypogonadism [91,92]. In this spe-
cific clinical context, the development of hypopituitarism
and GHD may further increase the fracture risk [93–95].
GHD in patients treated for acromegaly (acroGHD):
clinical/epidemiological studies
Notwithstanding these pathophysiological premises, the
clinical consequences of naı¨ve GHD in previously acrome-
galic subjects have been analyzed only in terms of body
composition and QoL outcomes in a so far limited number
of studies with small population samples. Race, personal
and family history, age, duration of acromegaly, degree of
GH/IGF-I excess exposure, treatment strategies, and du-
ration of GHD may be specific relevant confounding fac-
tors. Current studies suggest that BMI may be slightly
increased [12,96,97] or similar [17,23,98,99], in acroGHD
patients as compared to reference GHD and acromegalic
populations. Body composition analysis by dual-energy X-
ray absorptiometry (DXA) produced conflicting results. A
study on 10 acroGHD patients (nine of whom were women)
found no difference in body fat and lean mass, while
quadriceps muscle endurance was reduced in comparison
to 10 reference GHD patients [22]. It is worth noting,
however, that acroGHD patients included in the study
were more hypertensive, dyslipidemic, and diabetic than
their counterparts [22]. In a larger study, analysis byabdominal computed tomography and DXA of 31 acroGHD
patients found an increase in percent body fat, visceral
adipose tissue, and high-sensitivity C-reactive protein con-
centrations compared both to cured and active acromegalic
patients [98]. This may explain the increase in leptin
levels, a fat-derived hormone, seen in males with GHD
compared with non-GHD cured acromegalic subjects
[12]. Conversely, the prevalence of glucose abnormalities
and dyslipidemia was found to be comparable between
acroGHD and reference GHD groups [12,15], a circum-
stance which suggests that these populations may be
metabolically similar.
There is, at present, very limited data on cardiac
function, with one study documenting slight alterations
in diastolic function investigated by tissue Doppler imag-
ing in acroGHD patients as compared to healthy subjects
[96].
Despite the additional burden of GHD in this subset of
patients, it remains to be convincingly demonstrated
whether GHD can further aggravate the mortality risk
beyond that originating from previous acromegaly [100].
Results on QoL are more uniform, and support the
concept that low GH levels may contribute to an impaired
QoL in previously acromegalic patients. Analysis of KIMS
data documented that QoL assessed on the QoL-AGHDA
(QoL Assessment of Growth Hormone Deficiency in Adults)
scale was decreased in women with acroGHD compared to
those with GHD from other pituitary causes [21]. Wexler
et al. [42] found a strong correlation between QoL and GH
peak after GHRH+arginine test using QoL-AGHDA (36 in-
depth interviews), the symptom questionnaire (92 item
questionnaire), and the short-term health survey (SF-36,
36 items on physical and psychological well-being). In this
cohort of 45 acromegaly subjects, 26 GHD and 19 GH
sufficient, QoL was significantly poorer in subjects with
GHD by all scales and subscales (except the anxiety and
anger/hostility subscales of the symptom questionnaire)
also after controlling for potentially confounding factors
such as gender, BMI, radiation therapy, or other hormone
deficiencies [42].
Replacement therapy of GHD in (over)treated
acromegaly (acroGHD): pros and cons
In non-acromegalic adult populations with hypopituitarism,
replacement therapy with recombinant human GH (rhGH)
has been shown to reverse many systemic abnormalities
associated with GHD. Body composition and QoL can
improve within a few months after starting rhGH therapy
[101], while increases in bone mineral density (BMD) are
usually achieved in longer time-periods [102,103]. Reduc-
tions in total body fat and visceral adipose tissue have been
observed in hypopituitary patients treated with rhGH [104],
and are usually paralleled by improvements in serum lipo-
proteins [105], also when rhGH therapy is added on top of
maintenance statin therapy [106]. Conversely, if GHD is left
untreated, or if rhGH treatment is suspended, deterioration
of QoL, cardiovascular risk factors, and cardiac performance
is observed [105,107]. Importantly, insulin-resistance and
raised blood glucose levels may develop at the beginning
of rhGH therapy, particularly in patients exhibiting an
adverse risk profile at baseline such as high BMI [108].15
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en into consideration, studies on the effects of short- or
long-term rhGH therapy have generated conflicting results
(Table 2). In a sub-analysis of the KIMS database, 6 month
rhGH therapy determined no statistically significant im-
provement of QoL, BMI, waist circumference, or blood
pressure in acroGHD patients, although a positive trend
was registered for these clinical end-points [21]. In a
subsequent 6 month prospective study on 15 patients ran-
domized to rhGH compared to 15 patients randomized to
placebo, the authors reported about 10% reduction (treat-
ment vs placebo) in body fat mass, 14% and 7.8% decrease
in visceral and subcutaneous abdominal adipose tissue,
respectively, and an increase in fat-free mass of 1.4 kg
[51]. In the same study, QoL measured by the AGHDA
improved with rhGH, as did five of eight SF-36 subscales
(physical health, vitality, mental health, social function-
ing, and general health) and one of four symptom ques-
tionnaire subscales (somatic symptoms). In the rhGH-
treated arm, improvements in body composition and ab-
dominal adipose tissue were greater in patients with lowerTable 2. Results of studies investigating the effects of recombina
growth hormone deficiency (GHD) caused by overtreatment of ac
Refs n Sex
(M/F)
Median/mean
age (years)
Starting daily
dose of rhGH
Duration
(months)
Re
[21] 40 14/26 49.3 0.006 mg/kg 6 " 
# 
[22] 10 1/9 57.6 0.36 mg 24 ""
# 
" 
$
[23] 10 4/6 46 0.2-0.3 mg 36 ##
""
# 
" 
$
[24] 115 44/71 49.8 0.2 mg 60 ##
""
" 
$
[51] 15 6/9 0.003–0.006 mg/kg 6 ##
""
# 
" 
$
H
[97] 65 27/38 53 0.28 mg 37 $
##
""
[107] 9 0/9 44 0.003–0.006 mg/kg 6 ""
[109] 16 8/8 56 0.2 mg 12 ""
##
# 
" 
$
aSymbols: "", statistically significant increase; ##, statistically significant decrease; ", tre
difference with respect to the control group; **, significantly difference compared to t
bAbbreviations: BCM, body cell mass; BF, body fat; BMI, body mass index; BP, blood
crosslaps; PECW, extracellular water; F, female; FFM, fat-free mass; FN-BMD, femora
lipoprotein; hsCRP, high-sensitivity C-reactive protein; PINP, N-terminal propeptides o
ventricular ejection fraction; LVM, left ventricular mass; LS-BMD, lumbar spine-bone mi
MI, myocardial infarction; QoL, quality of life; REE, resting energy expenditure; TBN, tot
VAT, visceral adipose tissue.
16baseline GH peak after the GHRH+arginine test and
higher final rhGH dosing [51]. The same researchers
obtained similar favorable effects of rhGH therapy on
QoL in a group of GHD women with prior acromegaly
[107]. Conversely, a 2 year rhGH replacement therapy
study failed to document significant changes in body com-
position, while isometric knee flexor strength significantly
improved and a trend towards reduction was seen for total
and LDL cholesterol levels [22]. In line with these latter
data, a 1 year open-label prospective study found that
replacement with rhGH therapy was able to increase
IGF-I concentrations to the age- and gender-adjusted nor-
mal range, while neither echocardiographic parameters
nor any of the cardiovascular risk factors or QoL param-
eters changed significantly during rhGH treatment in this
clinical setting [109]. As expected, longer-term studies
found more remarkable effects of rhGH therapy [97]. In
a 3 year prospective controlled study, Giavoli et al. ob-
served a progressive improvement of QoL, total and LDL
cholesterol levels, and percent body fat in rhGH-treated
subjects, while a further deterioration of the lipid profilent human growth hormone (rhGH) treatment in patients with
romegalya,b
sults Undesired effects
(QoL)
(Waist, diastolic BP)
NS
 (BCM, knee flexion 608)
(BF, waist, BMI, HbA1c, LDL-C)
(HDL-C, TBN)
 (LBM, ECW, BP, TG)
MI (10%)**
CI (20%)**
 (BF, LDL-C, Total-C)
 (QoL)
(HDL-C)
(TG, BP, 2 h glucose)
 (BMI, waist, HbA1c)
None
 (Total-C, LDL-C)
 (QoL, HDL-C, HbA1c)
(Waist, BF)
 (BMI, BP, TG)
Neoplasms (8.7%)*
Cardiovascular disease (8.7%)*
Cerebrovascular disease (6%)*
Diabetes (16.5%)
Cardiovascular mortality (6%)**
 (BF, VAT)
 (FFM, REE, QoL)
(hsCRP)
(TBW)
 (BMI, CIMT, total-C, BP,
DL-C, LDL-C)
Arthralgia (33%)*
Edema (33%)*
Carpal tunnel symptoms (6.7%)*
 (BMI, waist, HDL-C, TG)
 (BP, total-C, LDL-C)
 (HbA1c)
Cardiovascular disease (3.8%)*
Stroke (1.7%)*
 (QoL) NS
 (PINP, CTX)
 (FN-BMD)
(Total-C, LDL-C, BF, LVM)
(TG, glucose, LBM, LVEF)
 (HDL-C, BP, Waist, LS-BMD, QoL)
NS
nd towards increase; #, trend towards decrease; $, unchanged; *, non-significant
he control group.
 pressure; CI, cerebral infarction; CIMT, carotid intimal-media thickness; CTX, b-
l neck-bone mineral density; HbA1c, glycated hemoglobin; HDL-C, high-density
f type I collagen; LBM, lean body mass; LDL-C, low-density lipoprotein; LVEF, left
neral density; M, male; n, number of patients treated with rhGH; NS, not specified;
al body nitrogen; TBW, total body water; TG, triglyceride; total-C, total cholesterol;
Box 1. Protocols of clinical interest
Protocol of insulin-tolerance test
Regular insulin is intravenously injected in a dose of 0.10 IU/kg.
Thereafter blood samples for GH and glucose are drawn every
15 minutes for 1 h and then every 30 min for the second hour. The
pharmacological stimulus is considered appropriate if plasma
glucose decline to values below 2.2 mmol/L and/or patients show
symptoms of hypoglycemia. Severe GHD is defined when GH peak
is below 3 mg/L.
Protocol of GHRH+arginine test
Arginine hydrochloride is intravenously administered at the dose
of 0.5 g/kg (i.v., up to a maximum of 30 g) over 30 min from 0 to
30 min. Thereafter, GHRH is intravenously administered at dosage
of 1 mg/kg. Blood samples for GH evaluation are taken at 0, 30, 45,
60, 90, and 120 min. Severe GHD is defined by a GH peak below
11.5 ng/ml for patients with a BMI less than 25 kg/m2, below 8.0 ng/
ml for a BMI of 25–30 kg/m2, and below 4.2 ng/ml for those with a
BMI greater than 30 kg/m2.
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effects of rhGH treatment were observed after 3 years
of follow-up in acroGHD compared to patients with
GHD post-(over)-treatment of non-functioning adenomas
[97]. rhGH was also shown to stimulate circulating mar-
kers of bone turnover without changes in BMD at the
lumbar spine and hip after 1 [109] and 2 years of therapy
[22]. In a recent analysis of data extracted from the KIMS
database on 115 acroGHD patients treated for up to 5 years
with rhGH, significant reduction of total and LDL choles-
terol levels, as well as a significant increase of HDL cho-
lesterol levels, were reported during rhGH therapy [24]. In
this analysis the change in lipids was not associated with
changes in BMI or body adiposity, a circumstance that
supports the beneficial role of rhGH therapy on lipoprotein
kinetics. In a subanalysis on fasting blood glucose and
glycated hemoglobin levels, rhGH therapy was found to
impair glucose levels in relation to attained BMI values,
thus substantiating the BMI-dependent risk of incident
diabetes in GHD treated with rhGH [24]. Collectively,
current data seem to suggest that long-term (3 years)
rhGH treatment might be needed to achieve significant
improvements in body composition and lipid profile in
acroGHD subjects. QoL status may motivate patients
and clinicians to start rhGH therapy and can be a useful
index of therapy effectiveness even in the short term.
Side effects in acroGHD patients are infrequent, mild,
and comparable between the rhGH-treated and placebo
groups or other reference groups [21,23,51,64,107]
(Table 2). These may include musculoskeletal pain, carpal
tunnel symptoms, or aggravation of hypertension
[110]. Nonetheless, safety issues have been recently raised
in prospective and long-term retrospective intervention
studies on rhGH therapy. In 10 acroGHD and their refer-
ence controls, Norrman et al. [22] witnessed a case of
myocardial infarction in one acroGHD woman 5 months
after initiation of rhGH, and cerebrovascular accidents in
one woman and one man (both previously irradiated) after
2 and 6 weeks of starting rhGH therapy, respectively. In an
analysis of the KIMS database, Feldt-Rasmussen et al. [21]
recognized a higher risk of stroke in acroGHD patients
before starting rhGH therapy, suggesting the potential
impact of previous GH excess and/or cranial irradiation
on this event. In a recent scrutiny of long-term KIMS data,
Tritos et al. [24] identified higher standard mortality rates
(SMR) for all-cause mortality in patients with acroGHD
treated with rhGH than in the reference GHD population
(SMR = 1.88, P <0.05), with women showing a slightly
increased risk over men (SMR = 1.51, P = 0.04). Compared
to the general population, rhGH treatment did not increase
the risk of all-cause mortality, nor the prevalence of cere-
brovascular accidents, malignant and benign brain
tumors, or the incidence of diabetes mellitus [24]. Cardio-
vascular mortality appeared to be increased in acroGHD on
rhGH compared to both the general population (observed/
expected = 2.89) and the reference GHD population
(SMR = 4.23, P = 0.004), with female gender acting as
the second-best predictor of cardiovascular mortality.
Based on these data, it seems reasonable to suggest a
prudent approach in considering rhGH therapy in
acroGHD patients with older age, elevated cardiovascularrisk, resistant hypertension, uncontrolled diabetes melli-
tus, and a long-term history of metabolic diseases or pre-
vious cranial irradiation. Because the neoplastic risk is
intrinsically increased in acromegaly [110], while fatal and
nonfatal malignancies are as prevalent in GH-treated
adults as in the general population [111], a prudent ap-
proach would also suggest that the risk of neoplasia should
be assessed in acroGHD patients who are candidates for
replacement therapy. In fact, some clinicians have started
rhGH therapy in patients with negative colonoscopy and in
women aged 40 years and older with negative mammo-
grams within 1 year before baseline visit [51]. However,
extensive interventional studies are required to definitive-
ly clarify the benefit/risk ratio of rhGH treatment in this
setting.
Recommendations for management of GHD in
(over)treated acromegaly (acroGHD)
There are no specific guidelines for the diagnosis and
treatment of GHD in patients with history of acromegaly.
However, several recommendations provided for the gen-
eral population of adults with pituitary diseases
[52,53,112,113] may be translated also to patients with
acroGHD, taking into account some peculiar aspects in-
herent to this latter clinical condition.
Based on the available data, we should test all patients
who meet the biochemical criteria of cure of acromegaly
after surgery and/or radiotherapy and radiosurgery, and
who have clinical features suggestive of GHD, such as poor
exercise capacity, impaired QoL, heart failure, adverse
lipid profiles, and low bone mass and/or fractures. An
IGF-I value below the reference range for age is highly
suggestive for severe GHD, particularly if other pituitary
deficiencies are already known [39,50]. However, the ab-
sence of other pituitary deficiencies and normal IGF-I
values do not exclude the diagnosis of GHD.
ITT is the gold standard for diagnosis especially in
irradiated patients (Box 1). In patients treated by surgery,
GHRH+arginine may be used as valuable alternative to
ITT (Box 1), especially in patients at risk for undesired
effects of hypoglycemia (i.e., high cardiovascular risk).
Patients should be tested 6 months after neurosurgery.
In patients treated with conventional radiotherapy, the17
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val since treatment [67]. Before testing GH reserve, all
other possible pituitary deficiencies should be corrected
because functional GHD may be caused by hypoadrenalism
(Giustina effect), hypogonadism, and hypothyroidism
[47,57,58]. Irradiated patients should be evaluated at reg-
ular intervals given that hypopituitarism and GHD may
develop as late as 10–15 years after treatment.
rhGH has been licensed for use in adult patients with
GHD for over 15 years. Early weight- and surface area-
based dosing regimens, derived from pediatric practice,
resulted in supraphysiological levels of IGF-I and in-
creased incidence of side effects, such as arthralgia and
peripheral edema [112,114]. These symptoms are also
common in active acromegaly, and subside after cure of
the disease. A ‘low-dose’ approach (0.7–3.5 mg/week) is in
line with current guidelines [52,112,113] and is also advis-
able in the context of acroGHD patients. This approach is
based on a tailored dose-titration strategy, which accounts
for inter-individual differences in GH sensitivity related to
age, gender, and various baseline characteristics. Because
dose requirements are greater in younger than older indi-
viduals, in women than in men, and in obese compared to
lean individuals [52,112], the starting dose is higher in
young (0.2 and 0.3 mg/day in men and women, respective-
ly) than older subjects (0.1 mg/day) [115], and is titrated
according to individual IGF-I levels and clinical respon-
siveness. At present, there is no consensus on the optimal
dose titration, final replacement dose, or ideal IGF-I values
to achieve on rhGH therapy in GHD patients with prior
acromegaly. Interventional studies have used weight-based
[21,109] or fixed-dose regimens of rhGH therapy [22–
24,51]. The achieved IGF-I levels were variable and com-
prised between –1.1 and +1.7 IGF-I standard deviation
scores. The likelihood of reaching target IGF-I levels recom-
mended by current guidelines was greater in mid- and long-
term interventional studies [24,64] than in short-term ones
[51,107]. As in treating GHD from other causes, dose titra-
tion of rhGH in patients with acroGHD should be based on
age, gender, and use of oral estrogens. At the Massachusetts
General Hospital [51,107] the starting doses were reported
to be as follows: 3 mg/kg daily in men 50 years and women
50 years not on oral estrogens; 5 mg/kg daily and 6 mg/kg
daily, respectively, in women <50 years not on oral estro-
gens and in women <50 years on oral estrogens; and 4 mg/kg
daily in men <50 years.
Treatment goals of rhGH therapy in acroGHD are (not
different from those of GHD from other causes): (i) correcting
the clinical alterations associated with GHD, (ii) achieving
IGF-I in the normal range, and (iii) avoiding overtreatment,
as reflected in side effects and high IGF-I levels. Replace-
ment therapy with rhGH is expected to yield clinical benefits
in acroGHD patients, and positive outcomes such as de-
creased body fat, increased lean mass, improvement in
C-reactive protein levels and QoL have been documented
to occur as soon as after 6 months of therapy [51,107]. After
at least 1 year of therapy, significant improvements in total
as well as LDL and HDL cholesterol become measurable
[23,24], while after the same interval the effect of rhGH
on BMD, echocardiographic parameters, and carotid IMT
is modest [96]. Objective parameters used to monitor18responsiveness to rhGH therapy, once maintenance rhGH
dose is achieved, should include body composition and fast-
ing lipid levels after 6 months and then yearly, in conjunc-
tion with evaluation of arterial blood pressure and
electrocardiogram. Particular caution is warranted in
patients with severe cardiometabolic impairment. Fasting
glucose levels should be carefully monitored during the
initial titration phase of GH replacement therapy and then
yearly during the long-term to identify the development of
hyperglycemia and/or diabetes mellitus. Indeed, GH re-
placement was shown to affect insulin sensitivity in GHD
patients, especially those with high starting BMI and met-
abolic syndrome [112,116]. A specific questionnaire for QoL
should be used before treatment, at 6 months, and then
annually after starting treatment. QoL may improve to a
lesser extent in patients suffering from musculoskeletal
disabilities caused by long-term exposure to GH excess. If
the initial bone DXA scan is abnormal, repeated scans are
recommended every 18–24 months to assess the need for
additional bone-treatment modalities. An independent as-
sessment of vertebral fractures by a radiological and mor-
phometric approach [117] also could be useful because BMD
is not a good predictor of fractures in GHD [91,118]. In fact,
early diagnosis of vertebral fractures is important to assess
the future risk of clinical osteoporotic fractures [92,119]. Be-
cause acromegaly is associated with high risk of colon
tumors [9] and rhGH could favor their development and
growth, colonoscopy should be regularly performed during
long-term treatment of acroGHD.
Concluding remarks
Current guidelines recommend GH treatment in GHD adult
patients in an appropriate clinical context, in other words,
documented pituitary disease. The first question that now
needs to be addressed is: are the acromegaly patients made
GHD by (over) treatment an appropriate clinical context?
Obviously, the story is slightly different compared to other
somewhat similar conditions, such as thyroid hormone sup-
plementation in hypothyroid thyroidectomized patients or
even in hypoadrenal ex-Cushing patients, because no doubt
exists in the scientific community concerning the necessity
of thyroxine/cortisol replacement, whereas no definitive
consensus exists on the risk–cost/benefit ratio of rhGH
treatment in the general GHD population [120]. However,
the patient with acromegaly could be thought to be even a
more appropriate candidate for rhGH treatment than the
other GHD patients because, paradoxically, excess and
deficiency of GH share many clinical characteristics which
may make the acromegaly patient more clinically vulnera-
ble than the other patients to the onset of GHD.
Having said this, two other questions may arise: is there
enough clinical evidence on the positive effects of GH
replacement to recommend universal screening for GHD
in ‘cured’ acromegaly patients? Has the issue of the dose of
GH, already largely debated in the general GHD popula-
tion, in combination with what IGF-1 level to target, been
adequately addressed in acroGHD? These questions are
legitimate considering the risk of double overtreatment
bringing the patient back to a status of ‘subtle acromegaly’.
Outstanding questions are summarized in Box 2. We know
from epidemiological data that acroGHD is not marginal,
Box 2. Outstanding questions
 Who are the acromegaly patients to be tested for GHD?
 Who are the patients with post-acromegaly GHD who should be
treated with recombinant GH?
 Which is the dose of recombinant GH to be used in patients with
post-acromegaly GHD?
 Which is the biochemical target of GH replacement in patients
with post-acromegaly GHD?
Feature Review Trends in Endocrinology and Metabolism January 2015, Vol. 26, No. 1if we proactively look for it. Acromegaly patients with
features likely to be complicated by GHD (osteoporosis,
heart failure, impaired QoL, and adverse lipid profile) are
probably the best candidates to be biochemically tested for
GHD. However, literature data on the positive effects of
GH substitution in this clinical setting are preliminary at
best and cannot sustain the recommendation for testing all
these acroGHD patients. Decisions should be made on an
individual basis, taking into account the risk profile of GH
substitution in these patients, because it is also true that
some acromegaly features could be worsened by rhGH
(oncologic and diabetogenic risk). In this context, a non
evidence-based decision – but a suggestion based on good
clinical sense – is to use starting doses lower than in other
GHD patients, targeting initially the low IGF-I range for
age. Finally, biochemical and clinical monitoring of the
rhGH-treated acroGHD patient should be strict to allow
careful assessment of short and long-term positive results
versus possible side effects.
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